Markets:

Overview

News

Currencies

International

Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.780 -0.040 (-1.42%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session ↗

November 17, 2022

Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67...

Via Benzinga

Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder ↗

November 17, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 17, 2022

Via Benzinga

Editas Medicine: Q3 Earnings Insights ↗

November 02, 2022

Editas Medicine (NASDAQ:EDIT) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Editas Medicine's Return On Capital Employed Insights ↗

August 10, 2022

Via Benzinga

Editas Medicine: Q2 Earnings Insights ↗

August 03, 2022

Editas Medicine (NASDAQ:EDIT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

S&P 500 Down 1%; Crude Oil Drops Sharply ↗

November 17, 2022

U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday.

Via Benzinga

BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday ↗

November 17, 2022

U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 17, 2022

Via Benzinga

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

November 17, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

BMO Initiates Coverage On This Gene Editing Spearhead ↗

June 17, 2022

Via Benzinga

Expert Ratings for Editas Medicine ↗

May 09, 2022

Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter:

Via Benzinga

What 5 Analyst Ratings Have To Say About Editas Medicine ↗

November 03, 2022

Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Editas Medicine Announces Third Quarter 2022 Results and Business Updates

November 02, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update

October 26, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting

October 13, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022 ↗

September 29, 2022

Upgrades

Via Benzinga

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗

September 16, 2022

Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.

Via Investor's Business Daily

3 Biotech Stocks Gaining Momentum

September 12, 2022

The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power.

Via MarketBeat

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

July 27, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates

July 26, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

The 3 Leaders of the Gene Editing Revolution ↗

July 08, 2022

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.

Via InvestorPlace

7 Moonshot Investments Upending a $10 Trillion Industry ↗

July 08, 2022

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.

Via InvestorPlace

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study ↗

June 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

June 07, 2022

Good morning! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

16 Stocks Moving in Tuesday's Pre-Market Session ↗

June 07, 2022

Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares rose 38% to $1.27 in pre-market trading following a Form 4 filing showing the purchase of 2,044,676 shares by CEO Salvatore Palella at an average price of...

Via Benzinga

Cathie Wood Is Selling Gene Editing Stocks. Here’s Why. ↗

June 02, 2022

Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?

Via InvestorPlace

Editas Medicine's Return On Capital Employed Insights ↗

May 19, 2022

Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter.

Via Benzinga

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗

May 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

All News about Editas Medicine, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today